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To determine the follow-up schedule in patients with non-muscle-invasive bladder cancer who had
remained recurrence-free for 5 or more years, we retrospectively reviewed 258 patients with Ta and T1
bladder cancer who had been free of recurrence for at least 5 years. Of these 258 patients, subsequent
recurrences developed in 100 patients. In spite of our recommendation that cystoscopic follow-up be done
at 12-month intervals for patients who remained recurrence-free for more than 5 years, 45 had been followed
at intervals of more than 12 months (range, 13-77 months) when the recurrences were found. Of 100
recurrent tumors, 20 (20.0%) showed bladder muscle invasion. Muscle-invasive cancer was identified more
often in the patients with cytoscopic intervals of more than 12 months than in those of less than 12 months
(35.6% versus 7.3%). Therefore, we recommend that cystoscopy be performed at intervals of less than 12
months in patients with non-muscle invasive bladder cancer for recurrence detection before tumors become
muscle invasive, even when patients remain free of recurrence for a long period.
(Hinyokika Kiyo 58 : 395-399, 2012)
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Fig. 1. Flow chart delineating followup and recurrences for 408 patients with
primary non-muscle-invasive bladder cancer.
が43例であった (Fig. 1）．症例の特徴を Table 1 に示
した．観察期間は再発を認めた群で長い傾向があっ
た．術後，207例で pirarubicin の膀胱内注入を行っ
た．注入方法は術後 3日目より 10 mg を連日 5日間，
































と有意に高かった (p＝0.0004，χ2 検定）(Table 2）．
12カ月以上の膀胱鏡間隔で再発が発見された45例で初
発癌の深達度，grade と再発癌の深達度を検討する













膀胱癌では BCG (bacillus Calmette-Guerin) 膀胱内注
入療法後でも40∼50％が再発する13)．多くは 5 年以
内に再発するが，Baniel ら2)によると BCG 膀胱内注
入療法後の T1G3 膀胱癌64例のうち22例で再発し，
そのうち 4例は50カ月以上経過してからの再発であっ
た．また Herr ら3)の BCG 膀注後10年以上の経過観察
によると，61例中再発した症例は42例（69％）で，25
例（41％）が進行した．そのうち 5例は 5年以上経過
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＜3 cm 78（78％) 140（88.6％)
















Table 2. Cystoscopic intervel and T stage of a
recurrent tumor
Ta/T1 T2 以上 計
6カ月未満 18（90％) 2（10％) 20
6 -12カ月 33（94.3％) 2（5.7％) 35
12-24カ月 11（61.1％) 7（38.9％) 18
24カ月以上 18（66.7％) 9（33.3％) 27






Table 3. Relationships between primary tumors
and recurrent tumors found with a
cystoscopy, in which the interval was
more than 12 months
初発癌
再発癌の深達度
Ta/T1 T2 以上 計
Ta
G1 5（100％) 0（0％) 5
G2 3（75％) 1（25％) 4
G3 1（100％) 0（0％) 1
小計 9（90％) 1（10％) 10
T1
G1 0 0 0
G2 13（65％) 7（35％) 20
G3 7（46.7％) 8（53.3％) 15
小計 20（57.1％) 15（42.9％) 35































間は 3カ月ごと， 3∼ 5年目は 6カ月ごと，その後は
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